This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yaldizli, O. Articles by Putzki, N. Search for Related Content Social Bookmarking                         What's this?

Review: Natalizumab in the treatment of multiple sclerosis

Cantonal Hospital, St. Gallen, Switzerland and Department of Neurology, University Clinic Duisburg-Essen, Germany, Norman.Putzki{at}kssg.ch

Norman Putzki

Cantonal Hospital, St. Gallen, Switzerland

Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing—remitting multiple sclerosis (RRMS). Natalizumab is generally well tolerated, but due to rare and potentially fatal side-effects, it was approved with a restricted-distribution format in 2006. Expert statements and the European Medical Agency recommend the use of natalizumab after failure of first-line disease-modifying therapies in patients with relapsing forms of MS. As part of the risk management plan, worldwide extensive safety programmes aim to provide more data on natalizumab safety in clinical practice. At the end of September 2008, 48 000 patients have received natalizumab and 18 000 patients are on treatment for at least 1 year. The assessment of risk and benefit is still ongoing.

Key Words: natalizumab • multiple sclerosis • disease-modifying therapy

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 2, 115-128 (2009)
DOI: 10.1177/1756285608101861


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?